Results 121 to 130 of about 178,479 (309)

Extracellular vesicle lipidomics liquid biopsy reveals systemic and tumor microenvironment metabolic reprogramming in ovarian cancer

open access: yesMolecular Oncology, EarlyView.
Extracellular vesicle (EV) lipidomic profiling of plasma and ascites from patients with high‐grade serous ovarian cancer and of ovarian cancer cell lines reveals enrichment of triglycerides (TGs), diacylglycerols (DGs), phosphatidylcholine (PCs), sphingomyelins (SMs), reflecting tumor metabolic reprogramming.
Shikha Rani   +9 more
wiley   +1 more source

Improved master theorems for divide-and-conquer recurrences

open access: yes, 2001
This paper presents new theorems to analyze divide-and-conquer recurrences, which improve other similar ones in several aspects. In particular, these theorems provide more information, free us almost completely from technicalities like floors and ...
Salvador Roura
core   +1 more source

RECURRENT PNEUMOTHORAX [PDF]

open access: yesThe American Journal of the Medical Sciences, 1889
n ...
openaire   +1 more source

Recurrences for generating polynomials

open access: yes, 2017
In this talk we consider sequences of polynomials that satisfy differential--difference recurrences. Our interest is motivated by the fact that polynomials satisfying such recurrences frequently appear as generating polynomials of integer valued ...
Hitczenko, Pawel
core   +1 more source

On Some k-Oresme Polynomials with Negative Indices

open access: yesCommunications in Advanced Mathematical Sciences
In this study, \textit{k-} Oresme polynomials with negative indices, which are the generalization of Oresme polynomials, were examined and defined. By examining the algebraic properties of recently defined polynomial sequences, some important identities
Serpil Halıcı, Elifcan Sayın
doaj   +1 more source

Predictive and prognostic biomarkers of Bacillus Calmette‐Guérin therapy failure in bladder cancer patients: A systematic review

open access: yesMolecular Oncology, EarlyView.
High‐risk bladder cancer is typically treated with Bacillus Calmette‐Guérin (BCG), but 30–40% of patients relapse. No FDA‐ or CE‐approved biomarkers currently predict or prognosticate BCG failure. We systematically reviewed the literature and identified 72 eligible studies, revealing several promising biomarkers associated with BCG treatment response ...
Rui Ribeiro‐Pereira   +7 more
wiley   +1 more source

Regulation of the lncRNA NEAT1 by p53‐ΔNp63 crosstalk modulates the DNA damage response and therapeutic efficacy in HNSCC

open access: yesMolecular Oncology, EarlyView.
In head and neck squamous cell carcinoma (HNSCC) p53 and p63 exert opposite roles on the transcription regulation of the lncRNA NEAT1. Under basal conditions, p53 levels are low and p63 represses NEAT1 expression. Upon genotoxic stress, p53 is rapidly induced, displacing p63 from the NEAT1 promoter leading to NEAT1 transcriptional activation and ...
Sara De Domenico   +5 more
wiley   +1 more source

Factorizations and representations of the backward second-order linear recurrences

open access: yes, 2007
We show the relationships between the determinants and permanents of certain tridiagonal matrices and the negatively subscripted terms of second-order linear recurrences.
Kilic, Emrah, Tasci, Dursun
core   +1 more source

APOBEC3 activity and DNA polymerase‐ε deficiency are associated with distinct IDH1 R132 hotspot mutations

open access: yesMolecular Oncology, EarlyView.
Isocitrate dehydrogenase 1 (IDH1) mutations are highly recurrent in multiple human cancer types, including cholangiocarcinoma and glioma. IDH1 R132C is the most common IDH1 mutation in cholangiocarcinoma and likely arises from APOBEC3A‐ or APOBEC3B‐mediated deamination.
Kelly E. Butler   +3 more
wiley   +1 more source

Expected number of atrial fibrillation recurrences.

open access: yes, 2019
Comparison of risk of future AF recurrences between AF subtypes. Dotted lines represent 95% confidence intervals.
Jakob Schroder (6812402)   +6 more
core   +1 more source

Home - About - Disclaimer - Privacy